Investigators studied a technique to replace the aortic valve that did not require surgery.
FORBES: Breakthrough Heart Valves: How Will Patients Decide?
In many cases, the aortic valve has to be replaced to correct aortic valve regurgitation.
Your surgeon removes your aortic valve and replaces it with a mechanical valve or a tissue valve.
In the future, however, transcatheter aortic valve implantation may be an option for treatment of aortic regurgitation.
The first trial will study alternatives to transfemoral approaches in 1, 000 patients considered ineligible for aortic valve surgery.
FORBES: Two Medical Societies Break New Ground To Test Medical Device
Aortic valve regurgitation can be eliminated with surgery, and you can usually resume normal activities within a few months.
The new study compared aortic valve surgery with the Edwards Lifesciences product.
FORBES: Breakthrough Heart Valves: How Will Patients Decide?
He holds a patent on a solution that can preserve organs and one on an aortic valve that can be implanted without highly invasive open-heart surgery.
Until recently the only option for patients whose aortic valve was stiff enough to cause them health problems was to undergo surgery to replace the valve.
FORBES: Breakthrough Heart Valves: How Will Patients Decide?
Traditionally, aortic valve replacement has been performed with open-heart surgery.
For now, this procedure is usually limited to individuals who have a narrowed aortic valve (aortic stenosis) rather than aortic regurgitation and are considered at high-risk for surgical complications.
The broad enthusiasm for TAVI (transcatheter aortic valve implantation) as it enters the marketplace has been partially offset by concerns about an increased risk of stroke associated with the procedure.
FORBES: Study Examines New-Onset Atrial Fibrillation After TAVI
That changed just over a year ago, when Edwards Lifesciences Corp. won approval to sell an artificial aortic valve flexible and small enough to fit into a catheter and wedged inside the bad one.
In a startling break with tradition, the American College of Cardiology and the Society of Thoracic Surgeons will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR).
FORBES: Two Medical Societies Break New Ground To Test Medical Device
In the trial, patients not eligible for aortic valve surgery will receive TAVR through transapical and transaortic approaches and will be compared with the results of patients in the original PARTNER A trial who received TAVR through the transapical approach.
FORBES: Two Medical Societies Break New Ground To Test Medical Device
Following the approval of the first device for transcathether aortic valve replacement therapy (TAVR) earlier this month, the Society of Thoracic Surgeons (STS) and The American College of Cardiology (ACC) have announced the launch of th e TVT Registry, a joint initiative that will monitor the rollout of the new technology.
In SEAS, Vytorin failed to do better than placebo at treating a heart valve disease called aortic stenosis, but it did reduce the risk of heart attacks, strokes and operations to unclog arteries.
The blockbuster cholesterol drug Vytorin failed to improve a rare heart valve condition called aortic stenosis and seemed to increase rates of cancer, a new study says, dealing another blow to the top-selling drug and its makers, Merck and Schering-Plough .
应用推荐